Philip Stimpson, Mediwatch chief executive commented’ “We are confident that this strategically important distribution agreement will deliver a significant revenue stream. The market for point of care diagnostics
Pfizer has stopped a Phase III clinical trial of Sutent early after the drug showed significant benefit in patients with advanced pancreatic islet cell tumors, also known as
Biothera, a biotechnology company, has received approval form the German regulatory authorities to conduct two open label, multicenter, randomized Phase II clinical trials studying Imprime PGG administered in
Icagen, a biopharmaceutical company, has initiated a Phase II proof-of-concept study of senicapoc, a novel orally available small molecule inhibitor of the KCa3.1 potassium ion channel, in patients
ValiRx, a cancer therapeutics and diagnostics company, has successfully completed its first collaborative stage with Cancer Research Technology, undertaken through the company’s biopharmaceutical division ValiPharma. Trials completed under
Gilead Sciences, a biopharmaceutical company, and CV Therapeutics have signed a definitive agreement pursuant to which Gilead will acquire CV Therapeutics for $20 per share in cash through
Mediscience Technology, a developer of minimally invasive autofluorescent-based technology for early detection of cancer, has expanded its technology platform with the completion of the acquisition of SensiVida Medical
Financial Data Gross margin stood at 53.4% of net sales, versus 53.2% in 2007, while gross profit amounted to EUR593 million compared with EUR566 million the year before.
Schering-Plough has received the FDA approval for new labeling of Pegintron and Rebetol combination therapy for treating chronic hepatitis C in patients three years of age and older
The new location offers room for anticipated growth and establishes a permanent headquarters for the company’s North America Region and US subsidiary, Karl Storz Endoscopy-America. The move is
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.